Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2023 | $9.00 → $1.50 | Outperform → Neutral | Robert W. Baird |
| 2/28/2022 | $30.00 → $20.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $25.00 → $9.00 | Buy | B of A Securities |
| 2/22/2022 | $35.00 → $29.00 | Neutral | BTIG Research |
| 2/22/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 2/22/2022 | $25.00 → $15.00 | Buy | Chardan Capital |
| 2/22/2022 | $35.00 → $29.00 | Buy | BTIG |
| 2/22/2022 | $30.00 → $4.00 | Outperform → Sector Perform | RBC Capital |
SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)
SC 13D - Q32 Bio Inc. (0001661998) (Subject)
SC 13D - Q32 Bio Inc. (0001661998) (Subject)
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t
424B3 - Q32 Bio Inc. (0001661998) (Filer)
10-Q - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price RequirementHomology Medicines, Inc. (NASDAQ:FIXX) today announced that it received notification ("Nasdaq Notification") from The Nasdaq Stock Market LLC ("Nasdaq") on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)). The Nasdaq Notification has no immediate effect on the listing of the Common Shares on the Nasdaq Capital Market. In accordance with the N
Gainers NGM Biopharmaceuticals (NASDAQ:NGM) shares moved upwards by 43.2% to $1.23 during Monday's after-market session. The company's market cap stands at $101.7 million. Cue Health (NASDAQ:HLTH) shares rose 35.38% to $0.22. The market value of their outstanding shares is at $34.0 million. Homology Medicines (NASDAQ:FIXX) stock increased by 12.46% to $0.64. The market value of their outstanding shares is at $36.8 million. Cue Biopharma (NASDAQ:CUE) shares moved upwards by 10.05% to $2.9. The company's market cap stands at $130.8 million. Cadrenal Therapeutics (NASDAQ:CVKD) shares increased by 9.68% to $0.78. The company's market cap stands at $10.1 million. Biophytis (NASDAQ:BPTS) sha
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 100 points on Thursday. The Dow traded down 0.39% to 34,853.42 while the NASDAQ fell 0.11% to 14,087.96. The S&P 500 also fell, dropping, 0.09% to 4,498.85. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month Leading and Lagging Sectors Utilities shares surged by 1% on Thursday. In trading on Thursday, energy shares fell by 2.2%. Top Headline Williams-Sonoma, Inc. (NYSE:WSM) reported better-than-expected third-quarter adjusted earnings. Williams-Sonoma posted non-GAAP earnings of $3.66 per share, versus market estimates of $3.35 per share. The company’s quarterly
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT
SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa
Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously
HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously
B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously
- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)